cover of episode Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

2017/7/7
logo of podcast Journal of Clinical Oncology (JCO) Podcast

Journal of Clinical Oncology (JCO) Podcast

Frequently requested episodes will be transcribed first

Shownotes Transcript

Normalization of PET-CT is a strong predictor   for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM)

Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study)